$0.39
4.20% today
Nasdaq, Apr 01, 06:18 pm CET
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Vaxart, Inc. Stock price

$0.41
-0.10 20.09% 1M
-0.44 52.06% 6M
-0.26 38.53% YTD
-0.89 68.69% 1Y
-4.63 91.92% 3Y
-1.36 77.01% 5Y
-24.89 98.39% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.01 3.37%
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Key metrics

Market capitalization $92.78m
Enterprise Value $64.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.24
P/S ratio (TTM) P/S ratio 3.23
P/B ratio (TTM) P/B ratio 1.57
Revenue growth (TTM) Revenue growth 288.94%
Revenue (TTM) Revenue $28.70m
EBIT (operating result TTM) EBIT $-66.29m
Free Cash Flow (TTM) Free Cash Flow $-45.32m
Cash position $51.72m
EPS (TTM) EPS $-0.35
P/E forward negative
P/S forward 18.19
EV/Sales forward 12.62
Short interest 5.42%
Show more

Is Vaxart, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Vaxart, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vaxart, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Vaxart, Inc. forecast:

Buy
100%

Financial data from Vaxart, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
29 29
289% 289%
100%
- Direct Costs 4.40 4.40
4% 4%
15%
24 24
774% 774%
85%
- Selling and Administrative Expenses 12 12
10% 10%
42%
- Research and Development Expense 74 74
9% 9%
259%
-62 -62
21% 21%
-216%
- Depreciation and Amortization 4.40 4.40
4% 4%
15%
EBIT (Operating Income) EBIT -66 -66
20% 20%
-231%
Net Profit -67 -67
19% 19%
-233%

In millions USD.

Don't miss a Thing! We will send you all news about Vaxart, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxart, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of the Board of Directors granted inducement equity awards to (i) seven new non-executive employees, covering an aggregate of 292,500 shares of its common stock, consisting of stock options to purchase 195,000 sha...
Neutral
Seeking Alpha
12 days ago
Vaxart, Inc. (NASDAQ:VXRT ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Ed Berg - SVP and General Counsel Steven Lo - CEO James Cummings - CMO Sean Tucker - Founder and CSO Phillip Lee - CFO Ray Stapleton - CTO Conference Call Participants Cheng Li - Oppenheimer Liang Cheng - Jefferies Operator Greetings and welcome to the Vaxart Business Update and Fourth Qu...
Neutral
GlobeNewsWire
12 days ago
Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025
More Vaxart, Inc. News

Company Profile

Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.

Head office United States
CEO Steven Lo
Employees 115
Founded 2004
Website www.vaxart.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today